Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1Phase 1/2 1

Status

Completed 3Recruiting 2

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Tumor-Agnostic 5Gastrointestinal 4Head & Neck 3Sarcoma 2Thoracic 1Lymphoid 1Gynecologic 1Genitourinary 1Dermatologic 1CNS 1Breast 1

Conditions

Neoplasms 5

Interventions

Surveys and Questionnaires 65pembrolizumab 56Gemcitabine 54Paclitaxel 51Blood Specimen Collection 45Carboplatin 44Bevacizumab 41Docetaxel 38Cisplatin 33Nivolumab 32Fluorouracil 31Capecitabine 28Radiotherapy 25Pemetrexed 25Irinotecan 25Standard of Care 24Interviews as Topic 24Magnetic Resonance Spectroscopy 23Leucovorin 22Erlotinib Hydrochloride 22atezolizumab 21Cetuximab 21Afatinib 21Oxaliplatin 19trametinib 18Exercise 18Ipilimumab 17Sorafenib 16Cyclophosphamide 16olaparib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Neoplasms × Indocyanine Green × Tumor-Agnostic × Clear all
NCT04752137 2026-04-24

Intraoperative Tumor Margin Identification With ICG Dye Imaging

Massachusetts General Hospital

Phase 2 Recruiting
100 enrolled
Tumor-Agnostic

Neoplasms

NCT04723810 2026-03-09

TumorGlow Intraoperative Molecular Imaging (IMI)

University of Pennsylvania

Phase 1/2 Recruiting
500 enrolled
Tumor-Agnostic

Neoplasms

NCT02280954 2018-03-20

818012

University of Pennsylvania

Phase 1 Completed
48 enrolled
Tumor-Agnostic

Neoplasms

NCT02621268 2018-03-20

ICG

University of Pennsylvania

Phase 1 Completed
48 enrolled
Tumor-Agnostic

Neoplasms

NCT01884584 2017-03-09

Potential Use of Indocyanine Green as a Fluorescent Agent for Definition of Surgical Margins in Cancer

Emory University

Phase 1 Completed
24 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡